- Home
- RGC vs CMPX Comparison
RGC vs CMPX Comparison
Compare RGC & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGC
- CMPX
- Stock Information
- Founded
- RGC 2014
- CMPX 2014
- Country
- RGC Hong Kong
- CMPX United States
- Employees
- RGC N/A
- CMPX N/A
- Industry
- RGC Medicinal Chemicals and Botanical Products
- CMPX Biotechnology: Pharmaceutical Preparations
- Sector
- RGC Health Care
- CMPX Health Care
- Exchange
- RGC Nasdaq
- CMPX Nasdaq
- Market Cap
- RGC 38.6B
- CMPX 291.8M
- IPO Year
- RGC 2021
- CMPX N/A
- Fundamental
- Price
- RGC $22.99
- CMPX $2.78
- Analyst Decision
- RGC
- CMPX Strong Buy
- Analyst Count
- RGC 0
- CMPX 9
- Target Price
- RGC N/A
- CMPX $12.67
- AVG Volume (30 Days)
- RGC 2.5M
- CMPX 929.9K
- Earning Date
- RGC 06-30-2025
- CMPX 08-11-2025
- Dividend Yield
- RGC N/A
- CMPX N/A
- EPS Growth
- RGC N/A
- CMPX N/A
- EPS
- RGC N/A
- CMPX N/A
- Revenue
- RGC N/A
- CMPX $850,000.00
- Revenue This Year
- RGC N/A
- CMPX N/A
- Revenue Next Year
- RGC N/A
- CMPX N/A
- P/E Ratio
- RGC N/A
- CMPX N/A
- Revenue Growth
- RGC N/A
- CMPX N/A
- 52 Week Low
- RGC $0.08
- CMPX $0.77
- 52 Week High
- RGC $83.60
- CMPX $4.08
- Technical
- Relative Strength Index (RSI)
- RGC 50.70
- CMPX 68.90
- Support Level
- RGC $9.39
- CMPX $2.50
- Resistance Level
- RGC $34.58
- CMPX $2.71
- Average True Range (ATR)
- RGC 13.45
- CMPX 0.19
- MACD
- RGC -2.79
- CMPX 0.01
- Stochastic Oscillator
- RGC 18.33
- CMPX 87.14
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.